Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC — Investor Relations & Filings

Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2025-02-03 Regulatory Filings
Country GB United Kingdom
Listing IL ROQ

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Share Purchase Agreement Signed - Sale of Lyramid
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number : 6233V' and concludes with information stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' RNS stands for Regulatory News Service, which is a primary channel for official company announcements in the UK. The content details a significant corporate action: the signing of a Share Purchase Agreement (SPA) for the sale of a subsidiary, including financial terms and strategic rationale. This type of material announcement, which is not a full financial report (like 10-K or IR) but a specific corporate event disclosure distributed via the regulatory news service, fits best under the general 'Regulatory Filings' category (RNS) as a catch-all for official, non-standardized announcements, or potentially a specific transaction type. Since the definitions do not explicitly cover 'M&A Announcement' outside of TAR (Merger/Takeover Bids), and this is a sale of a subsidiary, the most appropriate general regulatory disclosure category is RNS, as it is explicitly distributed via RNS and contains 'inside information' under UK MAR. Given the nature of the announcement (a material transaction disclosure distributed via RNS), RNS is the most fitting classification.
2025-02-03 English
Proposed Sale of Midkine Portfolio
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated '02 January 2025'. It announces a 'Proposed Sale of Midkine Portfolio' via a 'Term Sheet' and mentions the intent to sign a binding 'share purchase agreement (the "SPA")'. The document concludes with standard RNS boilerplate text, including the statement: 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure indicates a formal regulatory announcement disseminated through the RNS system, which is a general regulatory filing mechanism for the London Stock Exchange. Since the content is a specific corporate action announcement (M&A/Asset Sale) but is primarily functioning as a broad regulatory disclosure via RNS, and it is not a full financial report (like 10-K or IR), the most appropriate general classification for an LSE regulatory news service release that doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP) is the general Regulatory Filings category (RNS). Given the content is a specific transaction announcement, TAR might also be considered, but RNS is the mechanism of release and often used for these types of immediate, non-periodic disclosures.
2025-01-02 English
Director Share Distribution
Director's Dealing Classification · 100% confidence The document is an RNS announcement dated December 4, 2024, detailing share transactions by three Directors (Ajan Reginald, Dr Darrin Disley, and Sir Martin Evans) resulting from a trust distribution. The content explicitly falls under the category of reporting personal share transactions by company directors and executives, which corresponds directly to the 'Director's Dealing' definition. The filing type code for this is DIRS.
2024-12-04 English
Conversion of Convertible Loan Notes
Director's Dealing Classification · 98% confidence The document is an official announcement released via RNS (London Stock Exchange's news service) on November 7, 2024. The primary content details the conversion of Convertible Loan Notes (CLNs) into new ordinary shares by the company, Roquefort Therapeutics plc. Crucially, it includes detailed tables showing share transactions by directors (Stephen West, Ajan Reginald, Darrin Disley) following the conversion, explicitly labeled as 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM' under UK MAR regulations. This specific reporting of insider/PDMR transactions aligns directly with the definition of Director's Dealing (DIRS). While it involves capital structure changes (CAP), the focus and detailed disclosure structure are centered on director transactions.
2024-11-07 English
STAT-6 siRNA Presentation
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number' and contains an announcement regarding the presentation of experimental results at a congress. It is a formal communication disseminated via the RNS system, which is the London Stock Exchange's regulatory news service. The content is an update on scientific progress and business strategy, not a full financial report (like 10-K or IR), a transcript (CT), or a specific regulatory filing form. Since it is a general regulatory announcement distributed via RNS that doesn't fit the more specific categories like DIV, DIRS, or ER, the most appropriate classification is the general regulatory announcement category, RNS.
2024-11-06 English
Interim Results to 30 June 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results to 30 June 2024' and contains comprehensive unaudited condensed interim financial statements, including the Consolidated Statement of Comprehensive Income and the Consolidated Statement of Financial Position. It provides substantive financial data and management analysis for the six-month period, fitting the definition of an Interim/Quarterly Report (IR). It is not merely an announcement of a report, as it contains the full financial tables. H1 2024
2024-09-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.